The association of ADP-ribosylation with cell proliferation and ischemia-reperfusion injury suggests that it may be a suitable target for therapeutic control of revascularization-induced injury. The purpose of this study was to investigate the inhibitory actions of ADP-ribosylation inhibitors on restenosis. In organ culture, the poly(ADP-ribose) polymerase (PARP) inhibitor 3,4-dihydro-5-methylisoquinolinone (PD128763) was unable to prevent neointimal hyperplasia, whereas the arginine-dependent mono(ADP-ribosyl)transferase (ART) inhibitor meta-iodobenzylguanidine (MIBG) was highly effective (EC 50 21 M). Treatment with 3-aminobenzamide (3AB), a less potent ART inhibitor, also produced a significant reduction in neointimal hyperplasia. Single doses (25 mM) of MIBG and 3AB were also applied within a fibrin coagulum directly to the adventitial surface of the porcine femoral artery after balloon catheter injury in vivo. MIBG reduced the neointimal index, measured 14 days after angioplasty, by 82%, whereas 3AB was ineffective. However, when extended to 45 days, the neointimal index was not significantly decreased by MIBG treatment relative to control. Assessment of MIBG release from the fibrin glue showed that the bulk of the compound was eluted within 3 days, suggesting that the vehicle was not suitable for long-term delivery. On the other hand, direct infusion of MIBG into vessels was able to reduce neointimal hyperplasia over 14 days in organ culture. These data support the conclusion that the cellular retention characteristics of MIBG contribute significantly to the efficacy of this compound. Based on these results, ART, but not PARP, may be a credible target for therapeutic treatment of restenosis.
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Revascularization procedures, such as balloon angioplasty, stenting, and bypass graft surgery, were developed for the treatment of coronary and peripheral arterial disease. These procedures effectively alleviate the symptoms that result from an arterial obstruction due to atherosclerosis (e.g., angina and claudication) and improve quality of life for these patients. Traditionally, the long-term efficacy of these procedures has been limited by restenosis, a reduction of the vascular lumen at the site of intervention. Restenosis rates of 20 to 50% were associated with balloon angioplasty and bare metal stents; however, the introduction of drug-eluting stents (DES) has reduced the incidence of restenosis to Ͻ10% (Moses et al., 2003; Erglis et al., 2007) . Although restenosis rates are significantly lower, it nevertheless seems that DES do not improve long-term survival relative to bare metal stents (Kastrati et al., 2007; Spaulding et al., 2007) . This inconsistency may be due to the fact that DES are linked with delayed arterial healing, a condition that promotes late stent thrombosis (Joner et al., 2006) . Because late stent thrombosis may be an ongoing event , concerns have been raised regarding the continued use of DES (Webster and Ormiston, 2007; Win et al., 2007) . Consequently, there is renewed interest in evaluating alternative methodologies for controlling restenosis (Douglas, 2007; Weintraub, 2007) .
Paclitaxel, which prevents microtubule polymerization, and the immunosuppressive compound sirolimus (rapamycin) are the agents primarily used in DES (Slavin et al., 2007) . These drugs principally inhibit neointimal formation, having little or no effect on other stages of the vascular remodeling (elastic artery recoil, thrombosis) processes that lead to restenosis (Perin, 2005; García-García et al., 2006) .
On the other hand, numerous antiproliferative agents shown to have efficacy in vitro or in animal models have had only limited success in clinical trials (Andrés and Castro, 2003; Schömig et al., 2005) . Although the ineffectiveness of these compounds may be attributable to various physical impediments, such as inadequate dosing or compound toxicity, it also remains possible that better targets for therapeutic intervention remain to be identified.
ADP-ribosylation is a reversible post-translational modification in which an ADP-ribose moiety is transferred from NAD ϩ to an amino acid acceptor. This process exists in two forms. Poly(ADP-ribosyl)ation, which is primarily restricted to the nucleus, is catalyzed by poly(ADP-ribose) polymerase (PARP) in response to DNA damage (Miller, 1975) . The resultant modification of DNA-binding proteins causes dissociation from the DNA due to charge repulsion (Zahradka and Ebisuzaki, 1982) . PARP-1 inhibitors have been proposed for the treatment of ischemia-reperfusion injury (Szabó and Dawson, 1998) . However, their usefulness in managing neointimal hyperplasia after angioplasty has not been evaluated.
Mono(ADP-ribosyl)ation is catalyzed by mono(ADP-ribosyl)transferases (ART), which are present in viruses, bacteria, and eucaryotic cells (Corda and Di Girolamo, 2003) . These enzymes have been shown to regulate intracellular signaling, cell migration, cell proliferation, and cell differentiation Di Girolamo et al., 2005) . This laboratory has established that ART activation is required for the proliferation and migration of smooth muscle cells (SMCs) (Yau et al., 2003) . Consequently, ART inhibitors may likewise be capable of controlling restenosis.
The therapeutic potential of both PARP-1 and ART inhibitors has been examined for a variety of clinical conditions. For instance, 3-aminobenzamide (3AB) and isoquinolinone derivatives have been evaluated for protection against ischemia-reperfusion injury in both cardiac and brain tissues (Zingarelli et al., 1997; Plaschke et al., 2000) , whereas metaiodobenzylguanidine (MIBG) has been examined in clinical trials as a chemotherapeutic agent (Ekelund et al., 2001) . On the other hand, an appraisal of the effectiveness of these inhibitors on injury-induced revascularization has not been conducted. Therefore, we undertook this study to determine whether inhibitors of either poly(ADP-ribosyl)ation or mono-(ADP-ribosyl)ation could prevent restenosis after mechanical injury, using both ex vivo and in vivo models.
Materials and Methods
Organ Culture of Coronary Artery Rings. Angioplasty of the porcine left anterior descending coronary artery and culture of the vessel segments were conducted as described previously (Wilson et al., 1999) . In brief, hearts were obtained from the abattoir and the left descending coronary artery exposed. A standard balloon angioplasty catheter was inserted and inflated to 5 atm for 1 min. The artery was excised, cut into segments of 5 mm, and placed into culture with or without inhibitors. Vessels were harvested after 14 days, embedded in JB-4 resin, and sectioned (1-2-m thickness). Morphometry was used to determine the neointimal index as described below.
Porcine Femoral Angioplasty in Vivo. The procedure was approved by the University of Manitoba Animal Care committee and carried out in accordance with the guidelines set forth by the Canadian Council on Animal Care. Both left and right femoral arteries of male castrated pigs (30 -35 kg) were exposed from the bifurcation of the femoral and superficial femoral arteries to the point of femoral artery insertion into the groin area, treated with a 1:1 mixture of nitroglycerine/papaverine [1.0 ml of nitroglycerine (5 mg/ml) and 1.0 ml of papaverine (8.125 mg/ml)], and covered with a saline-soaked sponge. Atraumatic vascular clamps were placed at the proximal site (groin area) and at the distal site, just past the bifurcation of the femoral. An arteriotomy was made at the site of bifurcation, and an appropriately sized balloon (typically 6.0 ϫ 20 mm; the balloon/ artery diameter ratio was maintained at 1.2-1.4) was inserted through the arteriotomy in a retrograde manner. Once the balloon was in place, 20 mm from the point of insertion, the proximal vascular clamp was removed and the balloon was inflated to 6 atm for 1 min. The balloon was then deflated and removed, the proximal vascular clamp was reapplied, and the arteriotomy was closed. Tisseel (1.0 ml), fibrin glue; Baxter Healthcare Corp., Deerfield, IL) was applied along the length of the femoral artery from the arteriotomy to the proximal region of the vessel, encompassing the site of balloon injury. The incision was then closed, and the pigs were placed on antibiotics (amoxicillin) for 5 days. The pigs were euthanized 14 or 45 days after the angioplasty procedure, and the femoral arteries were harvested. The region that was subjected to angioplasty as well as the segment proximal to the injury were placed into OCT/Tissue Tek (Miles Laboratories Inc., Elkhart, IN), blocked, flash frozen in a dry ice/ethanol bath, and stored at Ϫ80°C.
Fibrin Glue Preparation. Fibrin glue, with and without test article, was prepared according to the manufacturer's instructions as described previously (Moon et al., 2004) . The femoral arteries were treated with either fibrin glue alone or fibrin glue plus compound in a random double-blind manner. The experiment was not unblinded until all of the tissue samples had been processed and neointimal index was quantified.
Morphometry. Sections of 7 m were prepared for each frozen artery segment, placed on glass slides, immersed in Streck tissue fixative (Streck Laboratories, Omaha, NE) for 10 min, washed extensively with phosphate-buffered saline (PBS), and finally stained for 1 min in Lee's methylene blue. The slides were serially washed with water, 70% ethanol, and water before being air-dried. Images were captured with a Dage-MTI CCD camera (Dage-MTI, Michigan City, IN) and used to calculate the neointimal index: intimal area/ medial area (Wilson et al., 1999) . All data were processed with the StainPoint software program (Lynx Graphics Ltd., Winnipeg, MB, Canada) that was developed specifically to reduce investigator subjectivity during this process. Both the surgeon and the pathologist responsible for analyzing the results were blinded to which artery received the treatment.
Pharmacokinetics. A fixed dose of MIBG (8 mg in 1.0 ml of fibrin glue) was applied to the left carotid artery of New Zealand White albino rabbits. Plasma samples were prepared from 2.0 ml of whole blood drawn from the marginal ear artery at 24 h before MIBG application, as well as at 2, 4, 12, 24, 36, 48, 72, 96, 120 , 240 h after dosing, and frozen at Ϫ70°C until analyzed. A 500-l aliquot of plasma, spiked with 10 ng of benzylguanidine (BG), was applied to a 1.0-ml Phenomenex Strata cyano-functionalized solid-phase extraction column (Phenomenex, Torrance, CA). The column was washed sequentially with 1.0 ml of borate (0.1 M) buffer, pH 11.0, water, and methanol, and the MIBG was eluted with 1.0 ml of hydrochloric acid (0.1 M) in methanol. The solvent was removed under vacuum, and the residue was reconstituted in 200 l of water. MIBG was quantified by high-performance liquid chromatography after derivatization with benzoin, using a modification of the method described by Sparidans et al. (1999) . This method was applicable to both pharmacokinetic and release kinetic studies. In brief, the samples were heated for 2 min at 98°C in the presence of 0.67 mM benzoin, 17 mM ␤-mercaptoethanol, 33 mM sodium sulfite, and 0.67 M NaOH. Subsequently, the samples were cooled on ice and adjusted to pH 9.2 with HCl. The samples were analyzed with a Phenomenex Luna C18(2) column (100 ϫ 4.6 mm, 5-m particle size) using a mobile phase of acetonitrile/water/0.5 M Tris-HCl, pH 8.0 (60:30:10). A Waters 474 fluorescence detector set (Waters, Milford, MA) to 320 nm (excitation) and 435 nm (emission) was used to measure the quantities of MIBG and BG. The amount of MIBG in the sample relative to the internal standard (BG) was determined by interpolation from a calibration curve prepared concurrently in control rabbit plasma.
Data Analysis. All data are presented as means Ϯ S.E.M., with analysis by one-way analysis of variance or the two-sample paired t test as indicated in the text. The Bonferroni test was used for means comparison. Differences were considered significant at P Ͻ 0.05.
Results

Prevention of Neointimal Hyperplasia in Vitro by
Inhibitors of ADP-Ribosylation. Neointimal proliferation in porcine coronary arteries in response to medial distention by balloon inflation was quantified after a 14-day incubation period ex vivo in the presence and absence of different classes of ADP-ribosylation inhibitors. Vessel injury produced a 2-fold increase (P ϭ 0.0004) in the neointimal index, a ratio of intimal area to medial area (Wilson et al., 1999) . Addition of 10 M PD128763 to the culture medium had no effect on neointimal formation; however, the presence of 5 mM 3AB resulted in a reduction of 60% (Fig. 1) . Whereas this reduction was not statistically significant from the untreated injured vessel population (P ϭ 0.17394), it was also not different from untreated noninjured vessels (P ϭ 0.11299). In contrast, 40 M MIBG reduced the neointimal index to basal levels. The conclusions reached in Fig. 1 were supported when a dose response was conducted for each of the compounds. PD128763 remained ineffective at twice the original concentration ( Fig. 2A) , whereas the slight effect obtained with 3AB was lost at lower concentrations (Fig. 2B) , specifically those that are capable of inhibiting PARP (Yau et al., 1998) . The response to MIBG was concentration-dependent (EC 50 ϭ 21 M; Fig. 2C ) and was effective only with continuous exposure for a period of at least 10 days (Fig. 2D) . No evidence of adverse effects was seen upon histological examination of the vessel segments exposed to MIBG (Fig. 2E) or vessels subjected to the other treatments (data not shown).
The reduction in neointimal index below baseline (uninjured control) obtained with MIBG treatment (Fig. 2C) is probably due a decrease in intimal area as a result of the loss of endothelial cells after balloon angioplasty. These data establish that inhibitors of ART but not PARP may be able to prevent restenosis.
MIBG Prevents Neointimal Hyperplasia after Balloon Angioplasty in Vivo. Based on the positive results obtained in vitro, the efficacy of MIBG was next tested in vivo. The femoral arteries of 11 pigs were exposed and subjected to balloon catheter injury. MIBG (25 mM) was subsequently mixed with fibrin sealant and applied in this format to the adventitial surface of the injured arteries, as described previously (Moon et al., 2004) . For each animal, one artery was randomly selected to receive fibrin glue containing MIBG while the contralateral artery received fibrin glue only. After 14 days, the animals were sacrificed, and each vessel was divided into balloon-injured and noninjured proximal regions. The vessel morphology was examined microscopically after staining with Lee's methylene blue, and digital images were captured and used to quantify the area of the intima/neointima and media. These data were generated from nine animals, because vessel rupture in two pigs during the angioplasty procedure resulted in their exclusion from the study. The neointimal index (intimal area/medial area) was subsequently calculated from these values.
Lee's staining of the vessel sections easily distinguished the medial and adventitial layers of the uninjured femoral artery, and a single layer of endothelial cells was visible on the luminal side of the internal elastic lamina (Fig. 3A) . In the injured vessel, a large neointimal was present (Fig. 3A, I ). In addition, the appearance of the medial layer differed considerably from that seen in the uninjured vessel. The MIBGtreated vessel, in comparison, more closely resembled the uninjured control in general appearance and in the size of the intimal region (Fig. 3A, T) . Quantitative analysis of the proximal and balloon-injured regions (Fig. 3B) showed that balloon angioplasty increased the neointimal index by 2.4-fold (0.027 Ϯ 0.003 versus 0.065 Ϯ 0.009). These results confirm that balloon injury resulted in a significant thickening of the intimal region that is consistent with induction of a lesion. Treatment of the balloon-injured segment with MIBG reduced neointimal formation by 82% (Fig. 3B) . Although there was variation in the response of individual animals as seen in the scatter diagram (Fig. 3C) , a pair-matched t test analysis confirmed that the reduction obtained with MIBG was statistically significant (P ϭ 0.0057). MIBG had no observable effect on the neointimal index of the treated proximal region relative to the untreated contralateral artery. These data establish that MIBG treatment can reduce neointimal hyperplasia in vivo and exhibit no apparent deleterious effects.
Evaluation of 3AB as an Inhibitor of Neointimal Hyperplasia. 3AB was applied at a dose of 25 mol/ml to five animals as described above. After 14 days, morphometric assessment of vessel sections was used to calculate the neointimal index of both proximal and injured regions of the treated and untreated arteries. Injury resulted in a 5-fold increase in the neointimal index (0.034 Ϯ 0.004 versus 0.181 Ϯ 0.039) of the nontreated vessel (Fig. 4) . Likewise, there was a 3-fold difference in relative neointimal area between proximal and injured sections (0.050 Ϯ 0.005 versus 0.160 Ϯ 0.042) of the 3AB-treated vessels. The lack of a 
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at ASPET Journals on April 8, 2017 jpet.aspetjournals.org Fig. 2 . Effect of inhibitor concentration and MIBG exposure time requirements on restenosis in vitro. Porcine coronary arteries were injured by inflation of a balloon catheter and placed into culture in the presence of the inhibitors. The neointimal index was determined after 14 days and is presented as means Ϯ S.E.M. for six samples. A-C, the effect of increasing PD128763, 3-aminobenzamide, and MIBG concentration. ‫,ء‬ P Ͻ 0.05 versus noninjured (NI) control; #, P Ͻ 0.05 versus untreated injured section. D, MIBG was added when the vessels were placed into culture and removed after the indicated number of days. The vessels were then kept in culture for the remainder of the 14-day period in the absence of inhibitor. The data are presented as means Ϯ S.E.M. for n ϭ 6. #, P Ͻ 0.05 versus day 0. E, vessel morphology as visualized with Lee's stain. N, uninjured and untreated control; I, injured; T, injured and MIBG-treated; n, neointima; m, media; a, adventitia. significant difference between the injured sections indicates that 3AB is unable to inhibit the formation of a neointima.
Evaluation of Long-Term Efficacy. To determine whether the effectiveness of MIBG could be sustained for more than 2 weeks, a long-term trial was initiated. Seven juvenile pigs were treated with MIBG as described previously. The extent of neointimal proliferation was measured by morphometry after 45 days. Although a 23% reduction in the neointimal index was obtained with MIBG treatment, the difference between the treated and untreated arteries was not statistically significant (Fig. 5A) .
The lack of effect over 45 days suggested that MIBG is either unsuitable for use as a therapeutic agent or the method of delivery was incompatible with our expectations. Therefore, we examined the release kinetics of MIBG from the fibrin glue. Fibrin glue was prepared according to the standard protocol and placed into PBS. Aliquots were removed over time, and the MIBG content was measured. This experiment revealed that the fibrin glue was completely depleted of MIBG within 2 h (Fig. 5B) . It was found that 3AB was also released rapidly (Fig. 5B) , which indicated that its release profile was not the cause of its inability to prevent neointimal hyperplasia in vivo (Fig. 4) . To verify that MIBG likewise rapidly diffused from fibrin glue in vivo, MIBGloaded fibrin glue was applied to the carotid artery of rabbits, and MIBG release into the serum was quantified. The highest amount of MIBG (55.8 ng/ml) was detected 2 h after application (Fig. 5C ). This amount was substantially lower at 4 h (31.3 ng/ml), and it continued to decrease until it reached 5 ng/ml (limit of accuracy for this method) at 36 h.
The data suggest that exhaustion of the fibrin glue carrier may account for the failure of MIBG to reduce restenosis over a period longer than 2 weeks. To address this question directly, we determined the effectiveness of MIBG when applied in the absence of the carrier in vitro. MIBG (1.0 ml, 25 mM solution) was infused into porcine coronary arteries with Fig. 3 . Evaluation of MIBG on neointimal hyperplasia in vivo. Femoral arteries subjected to balloon angioplasty were coated with fibrin glue or fibrin glue containing MIBG. The vessels were harvested 14 days postsurgery and frozen, and sections of 7 m were prepared. The morphology of both the region injured by balloon inflation (angioplasty) and the adjacent uninjured region proximal to the angioplasty site (proximal) was assessed (three sections per animal) after staining with Lee's methylene blue. A, representative femoral artery sections are shown for each treatment group. B, the neointimal index was calculated for each animal (n ϭ 9), and the data were plotted as means Ϯ S.E.M. C, the data for the angioplasty site are presented in a scatter diagram along with the means Ϯ S.E.M. ‫,ء‬ P Ͻ 0.05 versus untreated proximal control; #, P Ͻ 0.05 versus untreated angioplasty section. N, uninjured and untreated control; I, injured; T, injured and MIBGtreated; n, neointima; m, media; a, adventitia; iel, internal elastic lamina. Fig. 4 . Effect of 3-aminobenzamide on injury-induced neointimal hyperplasia in vivo. Femoral arteries subjected to balloon angioplasty were coated with fibrin glue or fibrin glue containing 3-aminobenzamide. The vessels were harvested 14 days postsurgery. The morphology of both the region injured by balloon inflation (angioplasty) and the adjacent uninjured region proximal to the angioplasty site (proximal) was assessed. The neointimal index was calculated for each section, and the means Ϯ S.E.M. are shown for the five samples. ‫,ء‬ P Ͻ 0.05 versus proximal region control.
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at ASPET Journals on April 8, 2017 jpet.aspetjournals.org a microperforated infusion catheter, and the vessels were placed into organ culture for 14 days. Balloon-injured vessels with and without infusion of saline served as controls. Injury produced a significant increase in the neointimal index (Fig.  5D ), in agreement with the results obtained previously (Figs.  1 and 2) . A similar increase in the neointimal index was obtained with saline infusion. In contrast, there was a 53% decline in the neointimal index with MIBG. Although the decrease was not statistically significant (P ϭ 0.40), MIBG treatment likewise was not distinguishable from the uninjured control (P ϭ 0.176). This is in comparison with the injured controls (P ϭ 0.037 without saline, P ϭ 0.014 with saline). From these results, it was concluded that the positive actions of MIBG could be obtained by saturating the vessel with compound in the absence of a depot, where it was retained over the minimal time period required to exhibit an inhibitory effect (refer to Fig. 2D ). Leaching of MIBG into the culture medium, and thus exposing the vessels to an effective concentration for the duration of the experiment, cannot explain our results, because the medium was changed every 2 days. This retention of MIBG by the vessel could explain the positive results seen over 14 days in vivo, even though fibrin glue was probably depleted of MIBG after the first few hours.
Discussion
Restenosis in response to balloon angioplasty, stent insertion, and bypass graft injury occurs as a result of damage to the arterial wall, and subsequent repair of the vessel requires smooth muscle cell activation. During this process, the phenotype of vascular SMCs is transformed from the contractile state to one that allows the cells to migrate and proliferate. In this study, we have shown, both ex vivo and in vivo, that MIBG, an inhibitor of arginine-dependent mono(ADPribosyl)ation, is capable of preventing restenosis, probably stemming from its ability to interfere with both SMC migration and proliferation (Yau et al., 2003) . In contrast, agents that inhibit poly(ADP-ribosyl)ation were ineffective. In addition, we have demonstrated that MIBG may be retained for significant duration within the vessel wall, a characteristic that could explain its long-term efficacy, even though the vehicle used for delivery was incapable of retaining the compound beyond a few hours. This is the first investigation to report the effectiveness of MIBG on neointimal hyperplasia due to injury-induced revascularization.
Based on our previous studies of SMCs and skeletal muscle cells (Yau et al., 2003 , it is evident that MIBG is an agent that has potent antiproliferative, antimigratory, and antidifferentiation properties in vitro. MIBG operates as a Fig. 5 . Assessment of fibrin glue as a drug delivery vehicle. A, the neointimal index of porcine femoral arteries 45 days after being subjected to balloon angioplasty. The graph presents the means Ϯ S.E.M. (n ϭ 7) obtained from arteries coated with fibrin glue alone or fibrin glue plus MIBG. B, the release of incorporated compounds from fibrin glue over time in vitro. MIBG (4 mg) and 3AB (3.4 mg) were incorporated separately into fibrin glue (1 ml), which was placed into 5 ml of PBS. Aliquots of 200 l were removed at the indicated times intervals, and the relative amount of the compounds was determined by measuring the optical density at 230 nm. The data represent the percentage of the total MIBG (f) and 3AB (Ⅺ) released from the fibrin glue and are presented as means Ϯ S.E.M. (n ϭ 7). C, the pharmacokinetics of MIBG release from fibrin glue is shown. Fibrin glue containing MIBG was applied to the carotids of white rabbits, and serum MIBG content was quantified in samples taken at the indicated times. Means Ϯ S.E.M. (n ϭ 10) are depicted. D, the results of an organ culture study evaluating the effectiveness of direct MIBG infusion. ‫,ء‬ P Ͻ 0.05 versus proximal region control.
decoy substrate for ART, thus preventing the modification of target protein with mono-ADP-ribose. In SMCs, this modification seems to regulate signal transduction pathways that affect transcription of the c-fos gene (Yau et al., 2003) . Consequently, it was predicted that MIBG would be effective in preventing neointimal proliferation after vascular injury. This premise was verified by quantifying the effect of MIBG on progression of neointimal formation with an ex vivo model of balloon angioplasty (Figs. 1 and 2) . In contrast, the PARP inhibitor PD128763 had no effect, convincingly establishing that PARP does not participate in phenotypic modulation of SMCs. These results are not surprising, based on our previous data showing that PD128763 was unable to block SMC proliferation or migration in response to growth factor stimulation (Yau et al., 2003) . In addition, these data suggest that ischemic injury is not a component of the vascular repair process, as has been previously suggested (Beller et al., 2006) , although induction of hypoxia-inducible factor-1␣ after angioplasty has been observed (Karshovska et al., 2007) . The slight inhibition in neointimal formation obtained with 3AB was concluded to represent inhibition of ART rather than PARP, as would be expected with the concentration that was used (Yau et al., 1998) .
The results obtained with the organ culture model have been predictive of success in vivo (Moon et al., 2004) . Therefore, we undertook to evaluate the antirestenosis properties of 3AB and MIBG in vivo. The agents were applied to the perivascular surface of the porcine femoral artery within a fibrin glue coagulum. Direct application of the compounds to a vessel surface was chosen because this approach avoids the potential problems associated with systemic delivery (Taal et al., 1996) . Furthermore, we previously established that fibrin glue can be successfully used for this purpose (Moon et al., 2004) . Release of MIBG and 3AB from this depot will result in their diffusion to the medial SMC layer, where they can potentially interfere with SMC migration and proliferation. On the other hand, if the adventitia plays an important role in the formation of neointima (Shi et al., 1996) , then placement of fibrin glue on the adventitial surface should prevent the migration of myofibroblasts to the lumenal surface.
Balloon injury of the porcine femoral artery resulted in the formation of a significant neointimal lesion in the region subjected to balloon injury but not in the adjacent uninjured (proximal) segment (Fig. 3) . Furthermore, the morphology of the medial layer differed from that of the control (Fig. 3A) . Treatment with MIBG reduced the lesion size 82% (Fig. 3B) , and vessel morphology resembled more closely the appearance of the uninjured control segments. The scatter diagram (Fig. 3C ) revealed that there is significant variability in the response to angioplasty-induced injury between animals, even though the animals were similar in size and age, and that the balloon/artery diameter ratio was maintained within a very narrow range. These data also indicate that the effect of MIBG was consistent regardless of lesion size.
One of the unknown factors of this investigation is the actual concentration of MIBG that is reached within the vascular tissue. In these experiments, a concentration of 25 mM was encapsulated within a 1.0-ml bolus of fibrin glue. The amount of MIBG applied was therefore three orders of magnitude higher than that required in our cellular studies (20 -50 M) (Yau et al., 2003) . This is also considerably higher than the 15 mg/kg reported to be a nontoxic dose in humans (Taal et al., 1996) . Nevertheless, no apparent damage to the tissues was observed (Fig. 3A) , suggesting that there is a high tolerance to MIBG, at least in this tissue.
Ideally, this study would have used the same vascular bed for all experiments. Cost and a lack of suitable equipment prohibited angioplasty of the coronary artery in vivo. Nevertheless, similar results were obtained. Thus, these data support our recent observations that show the responses obtained with human radial arteries were similar to those observed with both the femoral and coronary arteries of pigs (Moon et al., 2008) . These data might be unexpected given reports that SMCs isolated from different human vascular beds exhibit different responses to growth factor stimulation (Del Rizzo et al., 2002) . However, these variations in response differ only in the degree of change rather than the presence or absence of the response (Del Rizzo et al., 2002) .
Although we have emphasized that MIBG operates via its ability to inhibit SMC proliferation (Yau et al., 2003) , presumably by preventing their differentiation to the synthetic phenotype, MIBG may have additional effects on inflammation and/or thrombus formation. Jónsson et al. (1998) demonstrated that MIBG inhibits histamine receptor binding on endothelial cells and prevents histamine-induced inositoltrisphosphate and prostacyclin production. Thus, MIBG may be affecting the progression of restenosis, in part, by inhibiting the inflammatory response. Moreover, Hauschildt et al. (1998) have demonstrated that MIBG can prevent the production of tumor necrosis factor-␣ and interleukin-6 at the protein and mRNA level in human monocytes. Thus, if MIBG is able to inhibit the production of proinflammatory cytokines by monocytes, then the inflammatory response may be considerably reduced and thus any effects on SMCs decreased. This is highly relevant to restenosis, because both tumor necrosis factor-␣ and interleukins have been shown to stimulate migration of SMCs (Rectenwald et al., 2000) , and the inflammatory response has been proposed to play a role in intimal lesion formation (Biasucci et al., 1999) .
3AB is an inhibitor of ART at high concentration (Yau et al., 1998) , and thus it would be expected to block neointimal hyperplasia-like MIBG. Likewise, 3AB has been reported to protect against ischemia-reperfusion injury in the heart and brain (Zingarelli et al., 1997; Plaschke et al., 2000) . This ability to protect against injury suggested to us that perhaps an ADP-ribosylation event is closely associated with injury and the subsequent healing process, which in the vasculature would involve phenotypic modulation of SMC and mobilization of SMC and mononuclear cell types. From the results obtained in our study, however, this does not seem to be the case (Fig. 4) . Whereas it may be argued that the concentration of 3AB used in this study may have been too low, it would nevertheless have been adequate to inhibit PARP (Yau et al., 1998) . In conjunction with the observation that PD128763 also failed to limit neointimal proliferation (Fig.  1) , the conclusion that PARP inhibition is ineffective in preventing restenosis seems valid.
It is quite evident from the release studies performed (Fig.  5 ) that fibrin glue is not capable of serving as a long-term repository for sustained drug delivery. On the contrary, material embedded within the coagulum quickly disperses. Consequently, the degree of success obtained with MIBG over the 14-day trial period may be more attributable to its cellular retention characteristics rather than the mode of delivery. A jpet.aspetjournals.org combination of MIBG with a delivery vehicle that is capable of sustained release over several weeks may therefore prove more successful in reducing restenosis long-term. However, this approach would only be feasible for procedures that provide access to the perivascular surface of an artery, such as bypass graft surgery, rather than balloon angioplasty.
